二异丙基(乙氧基羰甲基)磷酸酯 | 24074-26-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 中文名称: 二异丙基(乙氧基羰甲基)磷酸酯
• 英文名称: ethyl (diisopropylphosphoryl)acetate
• 英文别名: diisopropyl (ethoxycarbonylmethyl)phosphonate；ethyl diisopropylphosphonoacetate；ethyl 2-di(propan-2-yloxy)phosphorylacetate
• CAS: 24074-26-8
• 化学式: C₁₀H₂₁O₅P
• mdl: MFCD00075267
• 分子量: 252.247
• InChiKey: YZEWJYIDAAGEHA-UHFFFAOYSA-N

物化性质

• 沸点：
  142-143 °C11 mm Hg(lit.)
• 密度：
  1.06 g/mL at 25 °C(lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：
  避免强氧化剂<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p>

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2931900090
• 储存条件：
  请将药品存放在密闭、阴凉干燥的地方保存。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Diisopropyl (ethoxycarbonylmethyl)phosphonate
CAS-No. : 24074-26-8

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
Precautionary statement(s)
Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S37/39 Wear suitable gloves and eye/face protection.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C10H21O5P
Molecular Weight : 252,24 g/mol
Component Concentration
Diisopropyl (ethoxycarbonylmethyl)phosphonate
CAS-No. 24074-26-8 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Nausea, Headache, Vomiting, To the best of our knowledge, the chemical, physical, and toxicological
properties have not been thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Oxides of phosphorus
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
Colour: colourless
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 142 - 143 °C at 15 hPa - lit.
boiling range
g) Flash point 113 °C - closed cup
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 1,06 g/cm3 at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agentsStrong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
Nausea, Headache, Vomiting, To the best of our knowledge, the chemical, physical, and toxicological
properties have not been thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine Pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  二异丙基(乙氧基羰甲基)磷酸酯 在 三甲基溴硅烷 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 以83%的产率得到Sodium;(2-ethoxy-2-oxoethyl)-hydroxyphosphinate
  参考文献：
  名称：

  Efficient and Selective Dealkylation of Phosphonate Diisopropyl Esters Using Me3SiBr

  摘要：

  DOI：

  10.1016/00404-0399(50)1334e-
• 作为产物：
  描述：

  (2-chloro-2-ethoxy-vinyl)-phosphonic acid dichloride 、 异丙醇 以 乙醚 为溶剂， 生成 二异丙基(乙氧基羰甲基)磷酸酯
  参考文献：
  名称：

  Moskva,V.V. et al., Journal of general chemistry of the USSR, 1976, vol. 46, p. 529 - 534

  摘要：

  DOI：

文献信息

• Aplyronine A, a potent antitumor macrolide of marine origin, and the congeners aplyronines B and C: isolation, structures, and bioactivities
  作者：Makoto Ojika、Hideo Kigoshi、Yoshifumi Yoshida、Takeshi Ishigaki、Masanori Nisiwaki、Itaru Tsukada、Masayuki Arakawa、Hisao Ekimoto、Kiyoyuki Yamada

  DOI：10.1016/j.tet.2007.02.011

  日期：2007.4

  isolated from the sea hare Aplysia kurodai together with the congeners aplyronines B (3) and C (4). The absolute stereostructure of aplyronine A (2) was determined by the instrumental analysis (mainly NMR and MS) and the enantioselective synthesis of the fragments obtained from chemical degradation of aplyronine A (2). The structures of aplyronines B (3) and C (4) were also elucidated. Cytotoxicity and

  从海兔Aplysia kurodai中分离到了一种有效的抗肿瘤大环内酯-Aplyronine A（2），以及同类的aplyronines B（3）和C（4）。通过仪器分析（主要是NMR和MS）和对苯丙氨酸A（2）的化学降解获得的片段的对映选择性合成，确定了苯丙氨酸A（2）的绝对立体结构。还阐明了鸭绿素B（3）和C（4）的结构。肾上腺素A（2）的细胞毒性和抗肿瘤活性进行了评估。
• Synthesis of beta-L-2'-deoxy nucleosides
  申请人：Storer Richard

  公开号：US20050059632A1

  公开（公告）日：2005-03-17

  An improved process for the preparation of 2′-modified nucleosides and 2′-deoxy-nucleosides, such as, β-L-2′-deoxy-thymidine (LdT), is provided. In particular, the improved process is directed to the synthesis of a 2′-deoxynucleoside that may utilize different starting materials but that proceeds via a chloro-sugar intermediate or via a 2,2′-anhydro-1-furanosyl-nucleobase intermediate. Where an 2,2′-anhydro- 1 -furanosyl base intermediate is utilized, a reducing agent, such as Red-Al, and a sequestering agent, such as 15-crown-5 ether, that cause an intramolecular displacement reaction and formation of the desired nucleoside product in good yields are employed. An alternative process of the present invention utilizes a 2,2′-anhydro-1-furanosyl base intermediate without a sequestering agent to afford 2′-deoxynucleosides in good yields. The compounds made according to the present invention may be used as intermediates in the preparation of other nucleoside analogues, or may be used directly as antiviral and/or antineoplastic agents.

  提供了一种改进的2'-改性核苷和2'-脱氧核苷的制备工艺，例如，β-L-2'-脱氧胸苷（LdT）。特别是，改进的工艺针对的是2'-脱氧核苷的合成，该合成可能使用不同的起始材料，但都通过氯糖中间体或通过2,2'-脱水-1-呋喃糖核苷中间体进行。当使用2,2'-脱水-1-呋喃糖碱基中间体时，会采用还原剂（如Red-Al）和隔离剂（如15-冠-5醚），它们能引起分子内位移反应，并形成所需核苷产品的高收率。本发明的一种替代工艺使用2,2'-脱水-1-呋喃糖碱基中间体而不使用隔离剂，也能以高收率获得2'-脱氧核苷。根据本发明制成的化合物可以作为制备其他核苷类似物的中间体，或者可以直接用作抗病毒和/或抗肿瘤剂。
• Stereoselective Preparation of Ceramide and Its Skeleton Backbone Modified Analogues via Cyclic Thionocarbonate Intermediates Derived by Catalytic Asymmetric Dihydroxylation of α,β-Unsaturated Ester Precursors
  作者：Linli He、Hoe-Sup Byun、Robert Bittman

  DOI：10.1021/jo001226n

  日期：2000.11.1

  yields. Furthermore, propargylic alpha-azido-beta-hydroxyester 10a is converted to D-erythro-sphingosine 2a via simultaneous reduction of the triple bond, azido, and ester functional groups with LiAlH(4), providing a highly concise and practical four-step synthesis of this key naturally occurring sphingolipid. The L-erythro stereoisomers are also available in high enantiomeric purity by the method described

  报道了一种新颖且有效的合成途径，制备神经酰胺1a和骨架骨架修饰的神经酰胺类似物1b，c。合成利用（催化的（E）-α，β-不饱和酯5a-c的a催化不对称二羟基化作为手性诱导步骤，产物1a-c，2a和13中的所需构型是通过在区域上进行区域选择性叠氮化物取代而产生的α，β-二羟基酯6a-c通过环状硫代碳酸酯中间体的α位。通过叠氮化物还原，N-酰化，酯还原（NaBH（4）/ LiBr）和三键桦木还原（Li，EtNH（2））的序列将叠氮基酯10a-c转换为相应的神经酰胺1a-c。 ）。这些七到八步的合成过程提供了具有出色立体控制效果的目标化合物1a-c，且总收率达30-42％。此外，通过与LiAlH（4）同时还原三键，叠氮基和酯官能团，将炔丙基α-叠氮基-β-羟基酯10a转化为D-赤型-鞘氨醇2a，从而提供了高度简洁和实用的四步合成方法关键天然存在的鞘脂。L-赤型立体异构体也可通过本文所述的方法以高对映体纯度获得。
• Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>
  作者：Michael J. Genin、Debra A. Allwine、David J. Anderson、Michael R. Barbachyn、D. Edward Emmert、Stuart A. Garmon、David R. Graber、Kevin C. Grega、Jackson B. Hester、Douglas K. Hutchinson、Joel Morris、Robert J. Reischer、Charles W. Ford、Gary E. Zurenko、Judith C. Hamel、Ronda D. Schaadt、Douglas Stapert、Betty H. Yagi

  DOI：10.1021/jm990373e

  日期：2000.3.1

  to dramatic improvements in activity against both Gram-positive and Gram-negative bacteria relative to unsubstituted counterparts. However, amide, ester, amino, hydroxy, alkoxy, and alkyl substituents resulted in no improvement or a loss in antibacterial activity. The placement of a cyano moiety on the azole often generates analogues with interesting antibacterial activity in vitro and in vivo. In particular

  已经制备了一系列新的氮碳连接的（偶氮基苯基）恶唑烷酮抗菌剂，以努力扩大此类抗生素的活性范围，使其包括革兰氏阴性菌。吡咯，吡唑，咪唑，三唑和四唑部分已用于取代利奈唑胺（2）的吗啉环。这些变化导致制备了对具有抵抗力的革兰氏阴性菌流感嗜血杆菌和卡他莫拉菌具有良好活性的化合物。未取代的吡咯基类似物3和1H-1,2,3-三唑基类似物6具有针对流感嗜血杆菌的MIC = 4微克/毫升，而粘膜炎莫拉氏菌= 2微克/毫升。为了在体外和体内研究其对抗菌活性的影响，还将各种取代基置于吡咯部分上。对于许多不能仅仅根据空间和唑环中氮原子的位置/数目而合理化的类似物，观察到活性上的有趣差异。活性的差异主要取决于整个唑系统电子特性的细微变化。相对于未取代的对应物，醛，醛肟和氰基唑通常可显着提高革兰氏阳性菌和革兰氏阴性菌的活性。然而，酰胺，酯，氨基，羟基，烷氧基和烷基取代基没有导致抗菌活性的改善或损失。氰基部分在唑上的放
• A Stereocontrolled, Efficient Synthetic Route to Bioactive Sphingolipids:  Synthesis of Phytosphingosine and Phytoceramides from Unsaturated Ester Precursors via Cyclic Sulfate Intermediates
  作者：Linli He、Hoe-Sup Byun、Robert Bittman

  DOI：10.1021/jo001225v

  日期：2000.11.1

  4-O-protected (E)-alpha,beta-unsaturated ester 5 (generated by dihydroxylation of 1-hexadecene, followed by oxidation to the aldehyde and Horner-Wadsworth-Emmons olefination), (ii) conversion to cyclic sulfate intermediate 7, and (iii) regioselective alpha-azidation of 7. Reduction of 4-O-protected 2-azido ester 8 via alpha-azidolactone 9 afforded phytosphingosine 1a. Staudinger reduction of the azido

  已经开发了一种高效且高度对映选择性的方法，用于制备D-核糖和L-ly​​xo-植物鞘氨醇（分别为1a，b）和植物神经酰胺（2a，b）。合成的关键步骤如下：（i）4-O保护的（E）-α，β-不饱和酯5的催化不对称二羟基化反应（通过1-十六碳烯的二羟基化反应，然后氧化成醛而生成） （Horner-Wadsworth-Emmons烯化反应），（ii）转化为环状硫酸盐中间体7和（iii）7的区域选择性α-叠氮反应。通过α-叠氮内酯9还原4-O-保护的2-叠氮基酯8得到了植物鞘氨醇1a 。施陶丁格还原8位叠氮基，然后在水性介质中原位N-酰化并用NaBH（4）/ LiBr还原酯官能度，从而提供了植物神经酰胺2a。通过使用类似的方法，合成了植物鞘氨醇1b。通过环硫酸盐中间体15以高产率从1-十六醇合成D-赤藓醇4、5-二氢鞘氨醇1c和D-赤藓醇4,5-二氢神经酰胺2c。C-2，C-3和C的所需构型通过本